Mirella Giordano

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al. · Annals of Oncology · 2014 · 90 citations · Full text

Medicine, Oncology, Chemotherapy +10

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Daniele Rossini, Carlotta Antoniotti, Sara Lonardi et al. · Journal of Clinical Oncology · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

Elisabetta Macerola, Barbara Loggini, Riccardo Giannini et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2015 · 75 citations

Medicine, Dermatology, Oncology +17

Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience

Liborio Torregrossa, David Viola, Elisa Sensi et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 55 citations · Full text

Medicine, Oncology, Pathology +14